Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea

• Conditions: Schizophrenia; Metabolic Syndrome

• Registration Number: NCT01477918
• Lead Sponsor: Asan Medical Center

Brief Summary

The aim of this study is to examine the prevalence of the Metabolic syndrome(MetS) in Korean patients with schizophrenia.

Primary objective:

• To investigate the prevalence of the MetS in Korean patients with schizophrenia

Secondary objectives:

• To compare the prevalence of the MetS among 3 groups according to antipsychotics: typical antipsychotic monotherapy group, atypical antipsychotic monotherapy group, 2 or more antipsychotics group (polypharmacy)

Detailed Description

Not available

Study Timeline

• Status Verified: 2011-11
• Study First Submitted: 2011-11-20
• Study First Submitted QC: 2011-11-22
• Last Update Submitted: 2011-11-22
• Study First Posted: 2011-11-23
• Last Update Posted: 2011-11-23
• Study Start: 2011-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Diagnosis of schizophrenia according to DSM-IV-TR
• Age between 18-65 years

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
prevalence of metabolic syndrome (MetS)		MetS will be diagnosed according to NCEP ATP III with the Asian-Pacific abdominal obesity criterion (≥90 cm in men, ≥85 cm in women); 3 or more of the following criteria; 1. fasting plasma glucose \>= 100 mg/dl or drug use to treat elevated glucose; 2. serum triglyceride (TG) \>= 150 mg/dl or drug use to treat elevated TG; 3. HDL cholesterol level \< 40mg /dl in males, \< 50 mg/dl in female or drug use to treat low HDL; 4. Systolic BP \>=130 mmHg, diastolic BP \>=85 or drug use to treat hypertension; 5. Abdominal obesity : above described

Trial Locations

Locations (1)

Asan medical center; 🇰🇷 Seoul, Korea, Republic of